

Highlights of This Issue 3119

SPECIAL FEATURES

CCR Translations

- 3121 Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility**
Daniel L. Hertz and James M. Rae
See related article, p. 3164
- 3124 Testosterone in Androgen Receptor Signaling and DNA Repair: Enemy or *Frenemy*?**
Melvin Lee Kiang Chua and Robert G. Bristow
See related article, p. 3310


CCR Drug Updates

- 3127 Talimogene Laherparepvec for the Treatment of Advanced Melanoma**
Patrick A. Ott and F. Stephen Hodi

Molecular Pathways


- 3132 Molecular Pathways: Targeting DNA Repair Pathway Defects Enriched in Metastasis**
Niall M. Corcoran, Michael J. Clarkson, Ryan Stuchbery, and Christopher M. Hovens

Review

- 3138 Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials**
 C. Norman Coleman, Geoff S. Higgins, J. Martin Brown, Michael Baumann, David G. Kirsch, Henning Willers, Pataje G.S. Prasanna, Mark W. Dewhirst, Eric J. Bernhard, and Mansoor M. Ahmed

CANCER THERAPY: CLINICAL

- 3148 Clinical and Molecular Characteristics of *NF1*-Mutant Lung Cancer**
Amanda J. Redig, Marzia Capelletti, Suzanne E. Dahlberg, Lynette M. Sholl, Stacy Mach, Caitlin Fontes, Yunling Shi, Poomima Chalasani, and Pasi A. Jänne

- 3157 Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors**
 Daniel D. Von Hoff, Monica M. Mita, Ramesh K. Ramanathan, Glen J. Weiss, Alain C. Mita, Patricia M. LoRusso, Howard A. Burris III, Lowell L. Hart, Susan C. Low, Donald M. Parsons, Stephen E. Zale, Jason M. Summa, Hagop Youssoufian, and Jasjit C. Sachdev

- 3164 Dose Escalation of Tamoxifen in Patients with Low Endoxifen Level: Evidence for Therapeutic Drug Monitoring—The TADE Study**
 Peter Fox, Rosemary L. Balleine, Clara Lee, Bo Gao, Bavanthi Balakrishnar, Alexander M. Menzies, Shang Heng Yeap, Sayed Sahanawaz Ali, Val Gebiski, Pamela Provan, Sally Coulter, Christopher Liddle, Rina Hui, Richard Kefford, Jodi Lynch, Mark Wong, Nicholas Wilcken, and Howard Gurney
See related commentary, p. 3121

- 3172 A Randomized Phase II/III Study of Naptumomab Estafenatox + IFN α versus IFN α in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis**
Robert E. Hawkins, Martin Gore, Yaroslav Shparyk, Vladimir Bondar, Oleg Gladkov, Tosho Ganey, Mihai Harza, Serhii Polenkov, Igor Bondarenko, Petr Karlov, Oleg Karyakin, Rustem Khasanov, Gunnar Hedlund, Goran Forsberg, Örjan Nordle, and Timothy Eisen

- 3182 Adjuvant Immunotherapy to Improve Outcome in High-Risk Pediatric Sarcomas**
Melinda S. Merchant, Donna Bernstein, Martha Amoako, Kristin Baird, Thomas A. Fleisher, Michel Morre, Seth M. Steinberg, Marianna Sabatino, Dave F. Stroncek, Aradhana M. Venkatesan, Bradford J. Wood, Matthew Wright, Hua Zhang, and Crystal L. Mackall

- 3192 Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer**
Maha Hussain, Sylvestre Le Moulec, Claude Gimmi, Rolf Bruns, Josef Straub, and Kurt Miller, on behalf of the PERSEUS Study Group

- 3201 Micrometastasis Volume in Lymph Nodes Determines Disease Recurrence Rate of Stage II Colorectal Cancer: A Prospective Multicenter Trial**
Hirofumi Yamamoto, Kohei Murata, Mutsumi Fukunaga, Tadashi Ohnishi, Shingo Noura, Yasuhiro Miyake, Takeshi Kato, Masahisa Ohtsuka, Yurika Nakamura, Ichiro Takemasa, Tsunekazu Mizushima, Masataka Ikeda, Masayuki Ohue, Mitsugu Sekimoto, Riichiro Nezu, Nariaki Matsuura, Morito Monden, Yuichiro Doki, and Masaki Mori

Table of Contents

3209 A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors

Alberto J. Montero, Deukwoo Kwon, Aurea Flores, Krisztina Kovacs, Jonathan C. Trent, Pasquale Benedetto, Caio Rocha-Lima, and Jaime R. Merchan

3218 Prognostic Impact of *IL6* Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy

Satoshi Matsusaka, Diana L. Hanna, Shu Cao, Wu Zhang, Dongyun Yang, Yan Ning, Yu Sunakawa, Satoshi Okazaki, Martin D. Berger, Yuji Miyamoto, Anish Parekh, Sebastian Stintzing, Fotios Loupakis, and Heinz-Josef Lenz

3227 Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors

Patricia M. LoRusso, Jing Li, Angelika Burger, Lance K. Heilbrun, Edward A. Sausville, Scott A. Boerner, Daryn Smith, Mary Jo Pilat, Jie Zhang, Sara M. Tolaney, James M. Cleary, Alice P. Chen, Lawrence Rubinstein, Julie L. Boerner, Adam Bowditch, Dongpo Cai, Tracy Bell, Andrew Wolanski, Allison M. Marrero, Yiping Zhang, Jiuping Ji, Katherine Ferry-Galow, Robert J. Kinders, Ralph E. Parchment, and Geoffrey I. Shapiro

3238 GTL001, A Therapeutic Vaccine for Women Infected with Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial



Pierre Van Damme, Myriam Bouillette-Marussig, Annick Hens, Ilse De Coster, Christophe Depuydt, Anne Goubier, Viggo Van Tendeloo, Nathalie Cools, Herman Goossens, Thierry Hercend, Benedikt Timmerman, and Marie-Christine Bisser

PERSONALIZED MEDICINE AND IMAGING

3249 Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer

Vinay Varadan, Hannah Gilmore, Kristy L.S. Miskimen, David Tuck, Shikha Parsai, Amad Awadallah, Ian E. Krop, Eric P. Winer, Veerle Bossuyt, George Somlo, Maysa M. Abu-Khalaf, Mary Anne Fenton, William Sikov, and Lyndsay N. Harris

3260 The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer

Francisco J. Sánchez-Martín, Beatriz Bellosillo, Mariona Gelabert-Baldrich, Alba Dalmases, Israel Cañadas, Joana Vidal, Alejandro Martinez, Guillem Argilés, Giulia Siravegna, Sabrina Arena, Klaus Koefoed, Laura Visa, Oriol Arpí, Ivan David Horak, Mar Iglesias, Christopher Stroh, Michael Kragh, Ana Rovira, Joan Albanell, Josep Tabernero, Alberto Bardelli, and Clara Montagut

3268 The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis

Matjaz Vogelsang, Carlos N. Martinez, Justin Rendleman, Anuj Bapodra, Karolina Malecek, Artur Romanchuk, Esther Kazlow, Richard L. Shapiro, Russell S. Berman, Michelle Krogsgaard, Iman Osman, and Tomas Kirchhoff

3281 Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing



Alexa B. Schrock, Garrett M. Frampton, Dana Herndon, Joel R. Greenbowe, Kai Wang, Doron Lipson, Roman Yelensky, Zachary R. Chalmers, Juliann Chmielecki, Julia A. Elvin, Mira Wollner, Addie Dvir, Lior Soussan-Gutman, Rodolfo Bordoni, Nir Peled, Fadi Braiteh, Luis Raez, Rachel Erlich, Sai-Hong Ignatius Ou, Mohamed Mohamed, Jeffrey S. Ross, Philip J. Stephens, Siraj M. Ali, and Vincent A. Miller

CANCER THERAPY: PRECLINICAL

3286 A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors




Marina Bacac, Tanja Fauti, Johannes Sam, Sara Colombetti, Tina Weinzierl, Djamila Ouaret, Walter Bodmer, Steffi Lehmann, Thomas Hofer, Ralf J. Hosse, Ekkehard Moessner, Oliver Ast, Peter Bruenker, Sandra Grau-Richards, Teilo Schaller, Annette Seidl, Christian Gerdes, Mario Perro, Valeria Nicolini, Nathalie Steinhoff, Sherri Dudal, Sebastian Neumann, Thomas von Hirschheydt, Christiane Jaeger, Jose Saro, Vaios Karanikas, Christian Klein, and Pablo Umaña

Table of Contents

- 3298** Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer–Initiating Cells and Is a Potent Target of Immunotherapy
Rena Morita, Yoshihiko Hirohashi, Toshihiko Torigoe, Satoko Ito-Inoda, Akari Takahashi, Tasuku Mariya, Hiroko Asanuma, Yasuaki Tamura, Tomohide Tsukahara, Takayuki Kanaseki, Terufumi Kubo, Goro Kutomi, Toru Mizuguchi, Takeshi Terui, Kunihiko Ishitani, Satoshi Hashino, Toru Kondo, Nozomi Minagawa, Norihiko Takahashi, Akinobu Taketomi, Satoru Todo, Masahiro Asaka, and Noriyuki Sato

- 3310** Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation
Mohammad Hedayati, Michael C. Haffner, Jonathan B. Coulter, Raju R. Raval, Yonggang Zhang, Haoming Zhou, Omar Mian, Emma J. Knight, Nina Razavi, Susan Dalrymple, John T. Isaacs, Aileen Santos, Russell Hales, William G. Nelson, Srinivasan Yegnasubramanian, and Theodore L. DeWeese
See related commentary, p. 3124

- 3320** Expression and Role of the ErbB3-Binding Protein 1 in Acute Myelogenous Leukemic Cells
Le Xuan Truong Nguyen, Li Zhu, Yunqin Lee, Lynn Ta, and Beverly S. Mitchell

- 3328** STAT3/5-Dependent IL9 Overexpression Contributes to Neoplastic Cell Survival in Mycosis Fungoides
 Pablo A. Vieyra-Garcia, Tianling Wei, David Gram Naym, Simon Fredholm, Regina Fink-Puches, Lorenzo Cerroni, Niels Odum, John T. O'Malley, Robert Gniadecki, and Peter Wolf

BIOLOGY OF HUMAN TUMORS

- 3340** Salivary Biomarkers for Detection of Oral Squamous Cell Carcinoma in a Taiwanese Population
Frederico Omar Gleber-Netto, Maha Yakob, Feng Li, Ziding Feng, Jianliang Dai, Huang-Kai Kao, Yu-Liang Chang, Kai-Ping Chang, and David T.W. Wong
- 3348** Mitochondrial Reprogramming Regulates Breast Cancer Progression
Anbarasu Kannan, Robert B. Wells, Subramaniam Sivakumar, Satoshi Komatsu, Karan P. Singh, Buka Samten, Julie V. Philley, Edward R. Sauter, Mitsuo Ikebe, Steven Idell, Sudeep Gupta, and Santanu Dasgupta

- 3361** A Novel Epigenetic Signature for Early Diagnosis in Lung Cancer
Angel Diaz-Lagares, Jesus Mendez-Gonzalez, David Hervas, Maria Saigi, Maria J. Pajares, Diana Garcia, Ana B. Crujeiras, Ruben Pio, Luis M. Montuenga, Javier Zulueta, Ernest Nadal, Antoni Rosell, Manel Esteller, and Juan Sandoval

- 3372** SIRT6 Overexpression Potentiates Apoptosis Evasion in Hepatocellular Carcinoma via BCL2-Associated X Protein–Dependent Apoptotic Pathway
Long-Kuan Ran, Yong Chen, Zhen-Zhen Zhang, Na-Na Tao, Ji-Hua Ren, Li Zhou, Hua Tang, Xiang Chen, Ke Chen, Wan-Yu Li, Ai-Long Huang, and Juan Chen

- 3383** Soluble B-Cell Maturation Antigen Mediates Tumor-Induced Immune Deficiency in Multiple Myeloma
Eric Sanchez, Abigail Gillespie, George Tang, Morgan Ferros, Nika Manik Harutyunyan, Suzie Vardanyan, Jillian Gottlieb, Mingjie Li, Cathy S. Wang, Haiming Chen, and James R. Berenson

- 3398** A Promyelocytic Leukemia Protein–Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma
Maria Dvorkina, Valentina Nieddu, Shalini Chakelam, Annalisa Pezzolo, Sandra Cantilena, Ana Paula Leite, Olesya Chayka, Tarik Regad, Angela Pistorio, Angela Rita Sementa, Alex Virasami, Jack Barton, Ximena Montano, Tanguy Lechertier, Nicola Brindle, Daniel Morgenstern, Morgane Lebras, Alan J. Burns, Nigel J. Saunders, Kairbaan Hodivala-Dilke, Luigi Bagella, Hugues De The, John Anderson, Neil Sebire, Vito Pistoia, Arturo Sala, and Paolo Salomoni

LETTERS TO THE EDITOR

- 3410** Ibrutinib Inhibits VLA-4–Dependent Adhesion in CLL—Letter
Antonella Zucchetto, Erika Tissino, Tanja Nicole Hartmann, Alexandre Chigaev, Giovanni Del Poeta, Alfonso Colombatti, and Valter Gattei
- 3412** Ibrutinib Inhibits VLA-4–Dependent Adhesion in CLL—Reply
Sarah E.M. Herman and Adrian Wiestner

Table of Contents

3413 Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCL—Letter
Hugo J.A. Adams and Thomas C. Kwee

3414 Molecular Profile and FDG-PET Metabolic Volume at Staging in DLBCL—Response
Anne-Ségolène Cottreau, Hélène Lanic, Sylvain Mareschal, Michel Meignan, Pierre Vera, Hervé Tilly, Fabrice Jardin, and Stéphanie Becker


 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a section of a skin biopsy from a mycosis fungoides patient. The staining displays a predominant infiltration of CD3 positive cells (blue) that encompass benign and malignant T cells accompanied by PU.1 cells (brown) in close proximity. For details, see the article by Vieyra-Garcia and colleagues on page 3328 of this issue.



Clinical Cancer Research

22 (13)

Clin Cancer Res 2016;22:3119-3415.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/22/13>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/22/13>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.